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A retrospective audit was carried out over an 18-month
period, comparing bacteraemia rates for each renal re-
placement modality (n ¼ 1997). Results are expressed as
bacteraemia episodes per 1000 patient days and estimated
annual costs in brackets (assuming an average cost of line
sepsis of £10,000):2,3 haemodialysis (HD) via a central
venous catheter (CVC) (n ¼ 403) 1.93 (£33,295.50); HD via
an AVF (n ¼ 670), 0.23 (£25,802.50); peritoneal dialysis
(n ¼ 157) 0.09 (£19,414.50) and renal transplantation
(n ¼ 1091) 0.03 (£22,109.50 in the ﬁrst year and £5109.50
for each subsequent year). Switching from CVC to AVF
(n ¼ 90) reduced the bacteraemia rate from 1.96 to 0.55
(p ¼ 0.01) and to transplant (n ¼ 38) from 2.72 to 0.73
(p ¼ 0.06).
Leermakers et al. report the median life-span of an
AVF and AVG to be 28.5 and 25.5 months, respectively,
while renal transplantation has a median survival of
13.5 years.1 These ﬁgures support an integrated RRT
strategy, including maximisation of opportunities for
renal transplantation as a cost-effective means to
minimise infection rates in patients with ESRD. In
particular, live donor renal transplantation should be
considered wherever possible as a means to reduce bac-
teraemia rates in patients currently dialysing via CVC rather
than switching to AVF/AVG, and organ allocation policies
based on clinical need (including vascular access status)
may be beneﬁcial.
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Re. ‘Re. ‘Cost-effectiveness of Vascular Access for
Haemodialyis: Arteriovenous Fistulas Versus
Arteriovenous Grafts”
McDermott et al. recognize infections as the most serious and
common complication of vascular access (VA) for hemodialysis
(HD) or peritoneal dialysis (PD) treatment, with subsequently
higher costs for these renal replacement modalities compared
with renal transplantation.1 This may be true for patients with
HD through central vein catheters, but certainly not for patients
receiving either PD or HD through arteriovenous ﬁstulae (AVF)
or arteriovenous grafts (AVG). Several publications have shown
similar outcome in terms of morbidity, hospital admission and
deathas a result of infectious complications inpatients onPDor
HD with an AVF or AVG as vascular access.2,3
The purpose of our study was to compare all costs
necessary to establish and maintain VA through an AVF or
AVG. This not only includes costs for treatment of infection,
but also in particular costs for access maintenance and
revision, like endovascular and/or surgical interventions, to
establish long-term patency.4
We do agree that renal transplantation is the ultimate goal
to treat young patients, in particular, with chronic renal fail-
ure and as in many centers, living-related kidney trans-
plantation is in our center a well-established method for
these patient groups. But one should keep in mind that
nowadays most patients in HD programs are very old with
multiple comorbidities, with a contra indication for renal
transplantation. These old patients, who are usually not on
thewaiting list for transplantation,may certainly beneﬁt from
an AVF, which, in addition, incurs lower healthcare costs to
main access patency in comparison with the use of AVGs.
Comparing renal transplantationwith theoutcomeofAVFand
AVG as HD vascular access, was not the purpose of our study.
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Re. ‘Great Saphenous Vein Diameter at the
Saphenofemoral Junction and Proximal Thigh as
Parameters of Venous Disease Class’
With interest we read the paper by Mendoza et al.1 The
authors propose a conversion factor, which uses measure-
ments of the great saphenous vein (GSV) at proximal thigh
(PT) level to estimate dimensions at the level of the
saphenofemoral junction (SFJ) and vice versa. This conver-
sion would then allow to recalculate dimensions of different
studies that only reported one of the dimensions of interest
(GSV or SFJ). We would like to comment on this conclusion.
In a previous study, we measured diameters at both
levels: at the PT the GSV diameter was 6.2  1.7 mm; at the
SFJ (measured exactly at the junction) the diameter was
7.5  2.0 mm.2 If we apply the proposed conversion factor
to our SFJ measurements, the estimated GSV diameter is
4.2  1.1 mm, which is signiﬁcantly different from the
diameter we actually measured (p < .001). Vice versa, the
estimated SFJ diameter is 11.2  2.8 (p < 0.001).
The main problem is the variable anatomical conﬁgura-
tion of the SFJ, which makes it more difﬁcult to standardize
diameter measurements. If measured “distal to the terminal
valve”1 the diameter will usually be larger than when
measured exactly at the junction.2 We would recommend,
therefore, that PT (or mid-thigh) diameter is measured in
transverse view at a site where the GSV has no focal dilation
and is still reﬂuxing.3 This will allow more accurate com-
parisons between studies.
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Re. “Great Saphenous Vein Diameter at the
Saphenofemoral Junction and Proximal Thigh as
Parameters of Venous Disease Class”
I greatly acknowledge your information which strengthens
the signiﬁcance of our concepts.
The high number of possibilities to measure the diameter
in the groin and the high variability of its shape explains our
different results. Our study refers to a measurement about
2e3 cm distal of the saphenofemoral junction (SFJ), as
proposed in the UIP Consensus Document of 2006.1 The
calculated conversion factor was applied only to those series
measuring at the same point as us; we included only them
in our literature list. Obviously the use of the conversion
factor is limited to those series using the same measure-
ment point.
Measuring at a different place, for example at the SFJ, as
in your publication, shows once more the high variability of
results at the different possible measurement points in the
groin. As you pointed out, the optimal solution would be to
measure the diameter of the great saphenous vein at the
proximal thigh instead.
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